- Previous Close
0.0320 - Open
0.0697 - Bid --
- Ask --
- Day's Range
0.0320 - 0.0320 - 52 Week Range
0.0250 - 0.6140 - Volume
28,412 - Avg. Volume
12,317 - Market Cap (intraday)
-- - Beta (5Y Monthly) -0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc.
cyclotherapeutics.com8
Full Time Employees
--
Fiscal Year Ends
Sector
Recent News: CYTHW
View MoreCompare To: CYTHW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTHW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-284.27%
Return on Equity (ttm)
--
Revenue (ttm)
870.73k
Net Income Avi to Common (ttm)
-24.8M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
928.01k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.05M